141 related articles for article (PubMed ID: 16502017)
1. Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer.
Tokunaga E; Oki E; Nishida K; Koga T; Yoshida R; Ikeda K; Kojima A; Egashira A; Morita M; Kakeji Y; Maehara Y
Breast Cancer Res Treat; 2006 May; 97(2):199-203. PubMed ID: 16502017
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation.
Cheung HW; Ching YP; Nicholls JM; Ling MT; Wong YC; Hui N; Cheung A; Tsao SW; Wang Q; Yeun PW; Lo KW; Jin DY; Wang X
Mol Carcinog; 2005 Aug; 43(4):237-45. PubMed ID: 15937956
[TBL] [Abstract][Full Text] [Related]
3. Promoter hypermethylation and silencing of CHFR mitotic stress checkpoint gene in human gastric cancers.
Kang HC; Kim IJ; Park JH; Shin Y; Park HW; Ku JL; Yang HK; Lee KU; Choe KJ; Park JG
Oncol Rep; 2004 Jul; 12(1):129-33. PubMed ID: 15201973
[TBL] [Abstract][Full Text] [Related]
4. Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers.
Mizuno K; Osada H; Konishi H; Tatematsu Y; Yatabe Y; Mitsudomi T; Fujii Y; Takahashi T
Oncogene; 2002 Apr; 21(15):2328-33. PubMed ID: 11948416
[TBL] [Abstract][Full Text] [Related]
5. CHFR gene is neither mutated nor hypermethylated in ovarian cancer.
Ludwig AH; Bujko M; Bidzinski M; Kupryjańczyk J
Cancer Detect Prev; 2007; 31(3):257-61. PubMed ID: 17673375
[TBL] [Abstract][Full Text] [Related]
6. Aberrant methylation of the CHFR gene in digestive tract cancer.
Morioka Y; Hibi K; Sakai M; Koike M; Fujiwara M; Kodera Y; Ito K; Nakao A
Anticancer Res; 2006; 26(3A):1791-5. PubMed ID: 16827108
[TBL] [Abstract][Full Text] [Related]
7. Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer.
Yanokura M; Banno K; Kawaguchi M; Hirao N; Hirasawa A; Susumu N; Tsukazaki K; Aoki D
Oncol Rep; 2007 Jan; 17(1):41-8. PubMed ID: 17143476
[TBL] [Abstract][Full Text] [Related]
8. Chfr inactivation is not associated to chromosomal instability in colon cancers.
Bertholon J; Wang Q; Falette N; Verny C; Auclair J; Chassot C; Navarro C; Saurin JC; Puisieux A
Oncogene; 2003 Dec; 22(55):8956-60. PubMed ID: 14654793
[TBL] [Abstract][Full Text] [Related]
9. Aberrant methylation of the CHFR gene in advanced hepatocellular carcinoma.
Sakai M; Hibi K; Kanazumi N; Nomoto S; Inoue S; Takeda S; Nakao A
Hepatogastroenterology; 2005; 52(66):1854-7. PubMed ID: 16334792
[TBL] [Abstract][Full Text] [Related]
10. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes.
Banno K; Yanokura M; Kawaguchi M; Kuwabara Y; Akiyoshi J; Kobayashi Y; Iwata T; Hirasawa A; Fujii T; Susumu N; Tsukazaki K; Aoki D
Int J Oncol; 2007 Oct; 31(4):713-20. PubMed ID: 17786301
[TBL] [Abstract][Full Text] [Related]
12. Aberrant methylation of the CHFR gene is frequently detected in non-invasive colorectal cancer.
Morioka Y; Hibi K; Sakai M; Koike M; Fujiwara M; Kodera Y; Ito K; Nakao A
Anticancer Res; 2006; 26(6B):4267-70. PubMed ID: 17201143
[TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
14. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
15. CHFR-associated early G2/M checkpoint defects in breast cancer cells.
Erson AE; Petty EM
Mol Carcinog; 2004 Jan; 39(1):26-33. PubMed ID: 14694445
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic inactivation of CHFR in human tumors.
Toyota M; Sasaki Y; Satoh A; Ogi K; Kikuchi T; Suzuki H; Mita H; Tanaka N; Itoh F; Issa JP; Jair KW; Schuebel KE; Imai K; Tokino T
Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7818-23. PubMed ID: 12810945
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
[TBL] [Abstract][Full Text] [Related]
18. Chfr defines a mitotic stress checkpoint that delays entry into metaphase.
Scolnick DM; Halazonetis TD
Nature; 2000 Jul; 406(6794):430-5. PubMed ID: 10935642
[TBL] [Abstract][Full Text] [Related]
19. [Detection and significance of APC gene promoter hypermethylation in serum of breast cancer patients].
Zhang JJ; Ouyang T; Wan WH; Xu GW; Deng GR
Ai Zheng; 2007 Jan; 26(1):44-7. PubMed ID: 17222366
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer.
Satoh A; Toyota M; Itoh F; Sasaki Y; Suzuki H; Ogi K; Kikuchi T; Mita H; Yamashita T; Kojima T; Kusano M; Fujita M; Hosokawa M; Endo T; Tokino T; Imai K
Cancer Res; 2003 Dec; 63(24):8606-13. PubMed ID: 14695171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]